Evidence map›Paper›PMID 27818567›Full record

Trial reportDisease markers2016

The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience.

Jarosław Dybko, Bożena Jaźwiec, Olga Haus, Donata Urbaniak-Kujda, Katarzyna Kapelko-Słowik, Tomasz Wróbel, Tomasz Lonc, Mateusz Sawicki, Ewa Mędraś, Agnieszka Kaczmar-Dybko and 1 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jarosław DybkoDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.ORCID 0000-0003-3555-2887
Bożena JaźwiecDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Olga HausDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Donata Urbaniak-KujdaDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Katarzyna Kapelko-SłowikDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Tomasz WróbelDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Tomasz LoncDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Jagiellonian University Hospital, Department of Anaesthesiology and Intensive Care, Krakow, Poland.
Mateusz SawickiDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Ewa MędraśDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Agnieszka Kaczmar-DybkoDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Lower Silesian Oncology Center, Department of Radiotherapy, Wroclaw, Poland.
Kazimierz KuliczkowskiDepartment of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.
Nicolaus Copernicus University · PLWroclaw Medical University · PLJagiellonian University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Sokal, Hasford, and EUTOS scores were established in different treatment eras of chronic myeloid leukemia (CML). None of them was reported to predict molecular response. In this single center study we tried to reevaluate the usefulness of three main scores in TKI era. The study group included 88 CML patients in first chronic phase treated initially with standard imatinib dose. All of them achieved major molecular response (MMR) in time points defined by European LeukemiaNet (ELN). 42 patients lost MMR in a median time of 47 months and we found a significant difference in MMR maintenance between intermediate-risk (IR) and low-risk (LR) patients assessed by Hasford score. All 42 patients were switched to second-generation TKI (2G-TKI) treatment. At 18 months of 2G-TKI therapy we have still found a significant difference in BCR-ABL transcript levels and MMR rate between IR and LR groups. We did not find any of the described differences discriminating patients by Sokal or EUTOS score. In this retrospective single center analysis we found Hasford score to be useful in predicting molecular response in first chronic phase of CML patients.

Indexed as

Severity of Illness IndexAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorFemaleFollow-Up StudiesFusion Proteins, bcr-ablHumansImatinib MesylateImmunoenzyme TechniquesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNeoplasm StagingAntineoplastic AgentsBiomarkers, TumorFusion Proteins, bcr-ablImatinib Mesylate

Identifiers

PMID27818567
PMCPMC5080519
OpenAlexW2530811845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.